The Kalios Beginner's Guide

What are peptides, actually?

Your body is a peptide factory. Right now, as you read this, it's making thousands of different peptides — short chains of amino acids that act as signals. Insulin is a peptide. Oxytocin is a peptide. The thing that makes you feel full after a meal? Also a peptide.

A peptide is basically a tiny protein. Proteins are long chains of amino acids folded into complex shapes. Peptides are the shorter chains — usually anywhere from 2 to about 50 amino acids long. Beyond that, scientists start calling them proteins.

When people talk about "taking peptides," they usually mean one of two things:

FDA-approved peptide drugs. These have been through clinical trials and are prescribed like any other medication. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide are peptides. So is insulin. So are a handful of others you've probably never heard of, used for everything from osteoporosis to hereditary angioedema.

Compounded or research peptides. These are peptides that exist in scientific literature — sometimes with significant evidence, sometimes barely any — but haven't gone through full FDA approval for most of their rumored uses. BPC-157, TB-500, ipamorelin, and most of what biohackers talk about on X live here.

That second category is where most of the conversation (and most of the confusion) happens.

Peptides vs. steroids — what's the actual difference?

This is one of the most Googled questions in the space, and the answer matters because the two categories get mentally lumped together even though they work completely differently.

Steroids (specifically anabolic androgenic steroids like testosterone, trenbolone, nandrolone) are synthetic versions of testosterone. They bind to androgen receptors throughout the body and drive muscle growth, strength, aggression, and a long list of side effects. They're powerful, well-studied, and come with predictable trade-offs: suppressed natural testosterone production, cardiovascular strain, liver stress depending on the form, and hormonal disruption that can last months or longer after you stop.

Peptides don't bind to androgen receptors and don't act like testosterone. Each peptide has its own specific target — a specific receptor, a specific enzyme, a specific signaling pathway. BPC-157 doesn't do what TB-500 does, which doesn't do what semaglutide does.

Some peptides (like growth-hormone-releasing peptides) can indirectly affect hormones, but the mechanism is fundamentally different from steroids. Most peptides people talk about for recovery, cognition, or longevity don't touch the androgen system at all.

Practical difference: steroids are a sledgehammer that hits everything. Most peptides are supposed to be a precision tool that hits one thing. Whether any given peptide actually is that precise is a different question — which is what the "Evidence" section on each Kalios compound page tries to answer.

The legal landscape — why this gets confusing fast

Here's the part that trips everyone up. When you hear a peptide described as "not FDA-approved," that doesn't automatically mean illegal. It could mean any of four very different things:

1. FDA-approved drugs. Semaglutide, tirzepatide, testosterone, insulin, and a few others. You get these with a prescription from your doctor, filled at a regular pharmacy. Clear legal status. Known quality standards.

2. Compounded drugs (503A pharmacies). Licensed compounding pharmacies can legally make custom-formulated medications for individual patients with a prescription. For peptides, that route is narrow. Sermorelin qualifies, because it was the active ingredient of an FDA-approved drug, so a telehealth clinic can prescribe it and a 503A pharmacy can fill it. BPC-157 and ipamorelin don’t: neither is legal to compound today (the FDA Tracker has where each one stands).

The catch: a peptide has to be either (a) part of an FDA-approved drug, (b) covered by a USP monograph, or (c) on the FDA's 503A Bulks List. In 2023, FDA moved a lot of peptides to "Category 2," effectively blocking compounding. In April 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. FDA's Pharmacy Compounding Advisory Committee voted on 7 of them on July 23–24, 2026, and the other 5 are scheduled before the end of February 2027. A committee vote is advisory, so none of the 12 is legal to compound today — see the FDA Tracker for the current state.

3. 503B outsourcing facilities. Larger-scale compounding facilities that can make batches of compounded medications for clinics. Same legal framework as 503A but at scale. More relevant to clinic operations than individual patients.

4. Research chemicals. Peptides sold with "for research use only, not for human consumption" labels. These are in a legal gray zone — technically legal to sell for research purposes, technically not intended for humans, practically bought and used by people anyway. Quality control is the buyer's problem. Purity varies wildly between vendors. No prescription. No pharmacy. No medical oversight.

Most of the compounds on Kalios fall into categories 2 or 4 depending on the specific peptide and the current regulatory state. The compound pages try to name which bucket each one is in.

How to read a Kalios card

Every compound has a card: on the Compounds page and on its goal’s page; the homepage shows three. Top to bottom:

Use tag. What people take it for, top left, then how it’s taken: daily shot, weekly shot, monthly shot (every four weeks or less often), shot (as needed, or on no one schedule), pill, nasal spray, cream, drops, IV drip or implant. A compound people take for more than one goal has one card, under its main goal, the use on its tag; the other goals’ pages list it under “Also taken for this”. The Khavinson peptides’ cards also sit together on the Bioregulators page.

Class tag. Under the name: what kind of compound it is, its mechanism in a few words, such as GLP-1, GH secretagogue or Bioregulator. On the Compounds page, the other goals people take it for are named beside it.

The hook. One line under the class tag: what it’s used for or sold as, then a number that checks the claim.

Evidence meter. Five squares, under the hook. It measures published human data on the compound itself, for the use on its tag (and growth hormone, on a Muscle & strength card): one square for no data, then Animal only, Human pilots, Controlled trials, and all five for an approved drug. Animal studies, unpublished results and data on a parent compound don’t move it.

Legal stamp. On the right, beside the name: where it stands in the US today, in one of three stamps. FDA approved: Prescribed by a doctor, made by a manufacturer. On a card, “for another use” under it means the approval is for a different use from the one on the card’s tag. Compounded Rx: On FDA’s 503A list — a licensed pharmacy can compound it for you. Gray market, with one of three lines: “FDA panel said yes on July 23–24, 2026 — not legal yet”, “FDA said no — on the do-not-compound list” or “No FDA ruling — not on any list”. A stack carries the stamp and line of its most restrictive member, named. Where a compound’s own facts don’t fit its stamp’s line, the line under its name says what does. One compound carries no stamp: RYZ101, given only in trials: nothing is sold and it can’t be compounded; where a stamp would be, its page and card say In trials only.

Red flag. A line in red with a red dot, under the meter, only when a specific harm has been observed, not a theory. Most cards have none.

Checked, last, is the date its page last changed.

On a compound’s page, a yellow line beside a paragraph means its status is waiting on a real event.

How people actually use peptides

Most therapeutic peptides are taken by injection — specifically subcutaneous injection, which means into the fat layer just under the skin (similar to how insulin is administered). A few are taken orally, sublingually (under the tongue), or intranasally. Very few are absorbed well by mouth because stomach acid breaks them down, which is why injection is the default.

A few concepts that show up constantly:

Reconstitution. Many peptides ship as a freeze-dried powder in a small glass vial. You mix it with bacteriostatic water (a sterile water with a small amount of preservative) before use. The ratio of water to peptide determines how concentrated each dose is, which then determines how many units on an insulin syringe equals your intended milligram dose. This is why there's a dosing calculator on Kalios — the math is annoying and easy to get wrong.

Cycling. The practice of using a peptide for a defined period (commonly 4–12 weeks) and then stopping for a similar period. The logic is usually one of two things: preventing tolerance/receptor downregulation, or limiting exposure to a compound with unknown long-term effects. Whether cycling is actually necessary for any given peptide is usually more theoretical than proven.

Stacks. Using multiple peptides together. Sometimes for complementary effects (a recovery peptide plus a growth hormone peptide), sometimes just because biohacker culture leans that way. Stack choices are usually anecdotal — there's rarely clinical evidence for specific combinations.

Storage. Reconstituted peptides typically need refrigeration and last somewhere between 2 weeks and a few months depending on the compound. Freeze-dried powder is far more stable — sometimes years if kept cold and dry. Each compound page on Kalios covers the specifics.

None of this is an instruction manual. It's context, so that when a compound page's tables give 2 mL of bacteriostatic water or a dose of 250 mcg twice daily, you know what those words mean.

The honest risk picture

Quality is the biggest practical risk. A peptide that arrives from a gray-market vendor might be the right compound at the right purity, might be underdosed, might be a completely different compound, or might be contaminated with something that shouldn't be in an injection. A third-party lab report (HPLC and mass spec) on a recent batch says what was in it when tested. Many vendors don't provide one. Prices vary 2–3× between sources and lower often correlates with lower quality, not a bargain.

The unknown-long-term problem. Most research peptides have never been studied in humans for long periods. Animal studies and short human trials tell you about acute effects. They don't tell you what happens to a 40-year-old who takes BPC-157 cycles for a decade. Nobody knows. Anyone claiming to know is selling something.

Specific red flags by compound. Some peptides have real, named risks. Melanotan II has been associated with new or changing moles and melanoma concerns. Dihexa targets a pathway (HGF/c-Met) that's also involved in tumor growth, a concern for anyone with a cancer history. Growth hormone secretagogues can affect blood sugar. Each compound page on Kalios lays out the specific risks for that specific peptide — this section is just to say: they exist, and they're compound-specific.

Interactions. Peptides can interact with prescription medications, other peptides, and various supplements. Most of these interactions are poorly studied. For anyone on a prescription medication, what adding a peptide does is a question for a licensed healthcare provider.

Where that leaves you

If you're still curious after reading all that, here's where things stand:

1. The approved compounds have the most human data. FDA-approved peptides have been through actual trials. For weight loss, semaglutide and tirzepatide have more evidence behind them than any research peptide. That's the established-but-boring answer.
2. A prescription is the legal path, for what is approved or can be compounded. Telehealth clinics that specialize in hormone and peptide therapy exist precisely because most primary care doctors don't follow this space. They're not perfect, but for those compounds they're a supervised legal path; some also supply gray-market peptides, which is their risk, not a change in the rule.
3. The research-chemical route is an experiment. No regulator checks what's in the vial, a stack adds unknowns, and for most research compounds what years of use do is unknown. A third-party lab report on a recent batch says what was in it when tested, and COA Check reads the report.
4. The compound pages on Kalios try to answer the same questions for each one: what it does, whether the evidence holds up, how people use it, what can go wrong, and what it costs. That's the rest of this site.

Kalios is a reference, not a recommendation. We take no position on whether you should use any peptide. The goal is just to make sure that whatever you decide, you're deciding with the best information we can honestly give you.